Response-Evaluating human trials: FDA's role
Science
.
2018 Jun 22;360(6395):1308-1309.
doi: 10.1126/science.aau0865.
Epub 2018 Jun 21.
Authors
S K Shah
1
,
J Kimmelman
2
,
A D Lyerly
3
,
H F Lynch
4
,
F G Miller
5
,
R Palacios
6
,
C A Pardo
7
,
C Zorrilla
8
Affiliations
1
Treuman Katz Center for Pediatric Bioethics, University of Washington and Seattle Children's Research Institute, Seattle, WA 98101, USA.
[email protected]
.
2
Biomedical Ethics Unit, McGill University, Montreal, QC H3A 1X1, Canada.
3
Center for Bioethics and Department of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
4
Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
5
Weil Cornell Medical College, New York, NY 10065, USA.
6
Instituto Butantan, São Paulo, Brazil.
7
Department of Neurology, Neurovirus Emerging in the Americas Study (NEAS), Johns Hopkins University, Baltimore, MD 21205, USA.
8
University of Puerto Rico School of Medicine, San Juan, PR 00921, USA.
PMID:
29930129
DOI:
10.1126/science.aau0865
No abstract available
Publication types
Comment
MeSH terms
Clinical Trials as Topic*
Humans
United States
United States Food and Drug Administration*